NPPB and myocardial infarction: The use of circulating natriuretic peptides (NPs), including BNP and NT-proBNP, as clinical biomarkers revolutionized the early recognition of patients with heart failure and ruled out other causes of dyspnea [43], as well as risk stratification after acute myocardial infarction [44].